The role of cytokines in the catabolic consequences of infection and injury

Journal of Parenteral and Enteral Nutrition

Volumn 22, Issue 3, 1998, Pages 156-166

  Chang, Hernan R ^a   Bistrian, Bruce ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADRENALIN; CATECHOLAMINE; CYTOKINE; GAMMA INTERFERON; GLUCOCORTICOID; GLUCOCORTICOID ANTAGONIST; GLUTAMINE; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; MIFEPRISTONE; SOMATOMEDIN; TUMOR NECROSIS FACTOR; UBIQUITIN;

HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION; INJURY; LEAN BODY WEIGHT; LIVER METABOLISM; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW; SKELETAL MUSCLE;

EID: 0031945999     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607198022003156     Document Type: Review

References (159)

1. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 229:869-871, 1985
2. Tracey KJ, Hesse DG, Manogue KR, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662-664, 1987
3. Ashkenazi A, Marsters SA, Capon DJ, et al: Protection against endotoxic shock by a tumor necrosis factor immunoadhesin. Proc Natl Acad Sci USA 88:10535-10539, 1991
4. Lesslauer W, Tabuchi H, Gentz R, et al: Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 21:2883-2886, 1991
5. Miethke T, Wahl C, Heeg K, et al: T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: Critical role of tumor necrosis factor. J Exp Med 175:91-98, 1992
6. Rothe J, Lesslauer W, Lötscher H, et al: Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF- mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798-802, 1993
7. Pfeffer K, Matsuyama T, Kündig TM, et al: Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457-467, 1993
8. Oliff A, Defeo-Jones D, Boyer M, et al: Tumor secreting human TNFa/cachectin induce cachexia in mice. Cell 50:555-563, 1987
9. Tracey KJ, Morgello S, Koplin B, et al: Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. J Clin Invest 86:2014-2024, 1990
10. Buck M, Houglum K, Chojkier M: Tumor necrosis factor-α inhibits collagen α1(I) gene expression and wound healing in a murine model of cachexia. Am J Pathol 149:195-204, 1996
11. Flores EA, Bistrian BR, Pomposelli JJ, et al: Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Invest 83:1614-1622, 1989
12. 2 production in rat skeletal muscle in fever is signaled by a macrophage product distinct from interleukin 1 or other known monokines. J Clin Invest 81: 1378-1383, 1988
13. Dinarello CE: Interleukin-1 and interleukin-1 antagonism. Blood 77:1627-1652, 1991
14. Ohlsson K, Björk P, Bergenfeldt M, et al: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 248:550-552, 1990
15. Alexander RH, Doherty GM, Buresh CM, et al: A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 173:1029-1032, 1991
16. Gauldie J, Sauder DN, McAdam KPWJ, et al: Purified interleukin-1 (TL-1) from human monocytes stimulates acute-phase protein synthesis by rodent hepatocytes in vitro. Immunology 60:203-207, 1987
17. Warner SJC, Auger KR, Libby P: Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells. J Immunol 139:1911-1917, 1987
18. Dinarello CA, Cannon JG, Wolff HA, et al: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163:1433-1450, 1986
19. Collait MA, Belin D, Vassalli J-D, et al: γ interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1 and urokinase genes which are controlled by short-lived repressors. J Exp Med 164:2113-2118, 1986
20. Ruschen S, Lemm G, Warnatz H: Spontaneous and LPS-stimulated production of intracellular IL-1βby sinovial macrophages in rheumatoid arthritis is inhibited by IFN-γ. Clin Exp Immunol 76:246-251, 1989
21. Ghezzi P, Dinarello CA-IL-1 induces IL-1. III. Specific inhibition of IL-1 production by IFN-γ. J Immunol 140:4238-4244, 1988
22. Knudsen PJ, Dinarello CA, Strom TB: Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin-1 in U937 cells. J Immunol 139:4129-4134, 1987
23. Knudsen PJ, Dinarello CA, Strom TB: Prostaglandins inhibit posttranscriptional interleukin-1 synthesis by increasing intracellular cyclic adenosine monophosphate. J Immunol 137: 3189-3194, 1984
24. Baracos V, Rodemann HP, Dinarello C A, et al: Stimulation of muscle protein degradation and prostaglandin E, release by leukocytic pyrogen (interleukin-1): A mechanism for the increased degradation of muscle protein during fever. New Engl J Med 308:553-558, 1983
25. Zamir O, Hasselgren PO, O'Brien W, et al: Muscle protein breakdown during endotoxemia in rats after treatment with interleukin-1 receptor antagonist (IL-1ra). Ann Surg 216:381-387, 1992
26. Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 54:1-78, 1993
27. Richards C, Gauldie J, Baumann H: Cytokine control of acute phase protein expression. Eur Cytokine Network 2:89-98, 1991
28. Kopf M, Baumman H, Freer G, et al: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368:339-342, 1992
29. Naitoh Y, Fukata J, Tominaga T, et al: Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious moving rats. Biochem Biophys Res Commun 155:1459-1463, 1988
30. Taga T, Narazaki M, Yasukawa K, et al: Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130. Proc Natl Acad Sci USA 89:10988-11001, 1992
31. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771-778, 1993
32. Strassman G, Fong M, Kenney JS, et al: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89:1681-1684, 1992
33. Oldenburg HS, Rogy MA, Lazarus DD, et al: Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. Eur J Immunol 23:1889-1894, 1993
34. Brouckaert P, Spriggs DR, Demetri G, et al: Circulating interleukin-6 during a continuous infusion of tumor necrosis factor and interferon-γ. J Exp Med 169:2257-2262, 1989
35. Jablons DM, Mule JJ, McIntosh JK, et al: IL-6/IFN-β-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol 142:1542-1547, 1989
36. Farrar MA, Schreiber RD: The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol 11:571-611, 1993
37. Watson J, Kelly K, Largen M, et al: The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J Immunol 120:422-424, 1978
38. Coutinho A, Meo T: Genetic basis for unresponsiveness to lipopolysaccharide in C57BL/10Cr mice. Immunogenetics 7:17-24, 1978
39. Freudenberg MA, Katschinski T, Kumazawa Y, et al: Interferon-gamma, a mediator of infection-induced sensitization towards endotoxin. IN Bacterial Endotoxins: Recognition and Effector Mechanisms, Dosen J, Alvarez CR, Munford RS, et al (eds). Excerpta Medica, Amsterdam, 1993, pp 197-209
40. Katschinski T, Galanos C, Coumbos A, et al: Gamma interferon mediates Propionibacterium acnes-induced hypersensitivity to lipopolysaccharide in mice. Infect Immun 60:1994-2001, 1992
41. Wherry JC, Schreiber RD, Unanue ER: Regulation of gamma interferon production by natural killer cells in scid mice: Roles of tumor necrosis factor and bacterial stimuli. Infect Immun 59:1709-1715, 1991
42. Yaegashi Y, Nielsen P, Sing A, et al: Interferon, a cofactor in the Interferon γ production induced by Gram-negative bacteria in mice. J Exp Med 181:953-960, 1995
43. Freudenberg MA, Galanos C: Tumor necrosis factor alpha mediates lethal activity of killed Gram-negative and Gram-positive bacteria in D-galactosamine-treated mice. Infect Immun 59:2110-2115, 1991
44. Freudenberg MA, Kumazawa Y, Meding S, et al: Gamma Interferon production in endotoxin-responder and non-responder mice during infection. Infect Immun 59:3484-3491, 1991
45. Heinzel FP: The role of IFN-γ in the pathology of experimental endotoxemia. J Immunol 145:2920-2924, 1990
46. Doherty GM, Lange JR, Langstem HN, et al: Evidence for IFN-γ as a mediator of the lethality of endotoxin and tumor necrosis factor-α. J Immunol 149:1666-1670, 1992
47. Bucklin SE, Russell SW, Morrison DC: Participation of IFN-γ in the pathogenesis of LPS lethality. Prog Clin Biol Res 338:399-406, 1994
48. Kohler J, Heumann D, Garotta G, et al: IFN-γ involvement in the severity of gram-negative infections in mice. J Immunol 151:916-921, 1993
49. Silva AT, Cohen J: Role of interferon-γ in experimental Gram-negative sepsis. J Infect Dis 166:331-335, 1992
50. Heremans H, Van Damme J, Dillen C, et al: Interferon-γ, a mediator of lethal lipopolysaccharide-induced Schwartzman-like shock reactions in mice. J Exp Med 171:1853-1869, 1990
51. Matthys P, Dillen C, Proost P, et al: Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-γ or anti-interleukin-6 antibody treatment protective effects and biphasic changes in blood cytokine levels. Eur J Immunol 23:2209-2216, 1993
52. Car BD, Eng VM, Schyder B, et al: Interferon γ receptor deficient mice are resistant to endotoxic shock. J Exp Med 179:1437-1444, 1994
53. Kamijo R, Le J, Shapiro D, et al: Mice that lack the interferon-γ receptor have profoundly altered responses to infection with bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide. J Exp Med 178:1435-1440, 1993
54. Huang S, Hendricks W, Althage A, et al: Immune response in mice that lack the interferon-γ receptor. Science 259:1742-1745, 1993
55. Buchmeier NA, Schreiber RD: Requirement of endogenous interferon-γ production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci USA 82:7404-7408, 1985
56. Zhao Y-X, Tarkowski A: Impact of interferon-γ receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis. J Immunol 155:5736-5742, 1995
57. Flynn JL, Chan J, Triebold KJ, et al: An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178:2249-2254, 1993
58. Kamijo R, Shapiro D, Le J, et al: Generation of nitric oxide and induction of major histocompatibility complex class II antigen in macrophages from mice lacking the interferon y receptor. Proc Natl Acad Sci USA 90:6626-6630, 1993
59. Marrack P, Blackmail M, Kushnir E, et al: The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells. J Exp Med 171:455-464, 1990
60. Nagaki M, Muto Y, Ohnishi H, et al: Hepatic injury and lethal shock in galactosamine-sensitized mice induced by the superantigen staphylococcal enterotoxin B. Gastroenterology 106:450-458, 1994
61. Matthys P, Mitera T, Heremans H, et al: Anti-gamma interferon and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in D-galactosamine-sensitized and unsensitized mice. Infect Immun 63:1158-1164, 1995
62. Matthys P, Dijkmans R, Proost P, et al: Severe cachexia in mice inoculated with interferon-γ-producing tumor cells. Int J Cancer 49:77-82, 1991
63. Langstein HN, Doherty GM, Fraker DL, et al: The roles of γ-interferon and tumor necrosis factor a in an experimental model of cancer cachexia. Cancer Res 51:2302-2306, 1991
64. Matthys P, Heremans H, Opdenakker G, et al: Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur J Cancer 27:182-189, 1991
65. Kaplan EH, Rosen ST, Norris DB, et al: Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82:208-212, 1990
66. Eggermont AM, Weimar W, Tank B, et al: Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-αA (rIFN-αa). Cancer Immunol Immunother 21:81-84, 1986
67. Krigel RL, Padavic-Shaller KA, Rudolph AR, et al: A phase I study of recombinant interleukin 2 plus recombinant β-interferon. Cancer Res 48:3875-3881, 1988
68. Legaspi A, Albert JD, Calvano SE, et al: Proteolysis of skeletal muscle in response to acute elevation of plasma cortisol in man. Surg Forum 36:16-18, 1985
69. Kayali AG, Young VR, Goodman MN: Sensitivity of myofibrillar protein to glucocorticoid-induced muscle proteolysis. Am J Physiol 252:E621-626, 1987
70. Hall-Angeras M, Hasseigren PO, Fischer JE: Corticosterone alone does not explain increased muscle proteolysis in septic rats. J Surg Res 48:368-372, 1990
71. Hasselgren PO, James JH, Benson DW, et al: Total and myofibrillar protein breakdown in different types of rat skeletal muscle: Effects of sepsis and regulation by insulin. Metabolism 38:634-640, 1989
72. Nelson DH: Cushing's syndrome. IN Endocrinology, Vol II, De Groot L, et al (eds), WB Saunders, Philadelphia, 1989, pp 1660-1675
73. Baumann H, Richards C, Gauldie J: Interaction among hepatocyte-stimulating factors, interleukin-1, and glucocorticoids for regulation of acute phase proteins in human hepatoma (Hep G2) cells. J Immunol 139:4122-4128, 1987
74. Hall-Angeras M, Zamir O, Hasselgren PO, et al: Effect of the glucocorticoid receptor antagonist RU 38486 on muscle protein breakdown in sepsis. Surgery 109:468-473, 1991
75. Zamir O, Hasselgren PO, von Allmen D, et al: The effect of interleukin-1α and the glucocorticoid receptor blocker RU 38486 on total and myofibrillar protein breakdown in skeletal muscle. J Surg Res 50:579-583, 1991
76. Zamir O, Hasselgren O, James H, et al: Effects of tumor necrosis factor or interleukin-1 on muscle amino acid uptake and the role of glucocorticoids. Surg Gynecol Obstet 177:27-32, 1993
77. Philibert D: RI 38486: An original multifaceted antihormone in vivo. IN Adrenal Steroid Antagonism, Agarwal MK (ed), Walter de Gruyter, Hawthorne, NY, pp 77-100
78. Parthasarathy S, Morales AJ, Murphy AA: Antioxidant: A new role for RU-486 and related compounds. J Clin Invest 94:1990-1995, 1994
79. Goldberg AL: Functions of the proteasome: The lysis at the end of the tunnel. Science 268:522-523, 1995
80. Mitch WE, Goldberg AL: Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 335:1897-1905, 1996
81. Baracos VE, DeVivo C, Hoyle DHR, et al: Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma Am J Physiol 268:E996-1006, 1995
82. Price SR, England BK, Bailey JL, et al: Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNA in rat muscle. Am J Physiol 267:C955-960, 1994
83. Price SR, Bailey JL, Wan X, et al: Muscle wasting in insulinopenic rats results from the activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. J Clin Invest 98:1703-1708, 1996
84. Price SR, Bailey JL, England BK: Necessary but not sufficient: The role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle. Miner Electrolyte Metab 22:72-75, 1996
85. 3H1 myocytes require an interaction between glucocorticoids and acidification. Proc Natl Acad Sci USA 93:1967-1971, 1996
86. Tiao GT, Fagan JM, Samuels N, et al: Sepsis stimulates nonlysosomal, energy dependent proteolysis and increases ubiquitin mRNA levels in rat skeletal muscle. J Clin Invest 94:2255-2264, 1994
87. Tiao GT, Fagan J, Roegner V, et al: Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J Clin Invest 97:339-348, 1996
88. Tiao GT, Hoblet S, Wang JJ, et al: Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest 99:163-168, 1997
89. Wing SS, Banville D: 14-kDa ubiquitin-conjugating enzyme: Sructure of the rat gene and regulation upon fasting and by insulin. Am J Physiol 267:E39-48, 1994
90. Hershko A, Ciechanover A: The ubiquitin system for protein degradation. Annu Rev Biochem 61:761-807, 1992
91. Dahlmann B, Kuehn L: The 20S/26S proteasomal pathway of protein degradation in muscle liver. Mol Biol Rep 21:57-62, 1995
92. Rivett AJ, Mason GGF, Thomson S, et al: Catalytic components of proteasomes and the regulation of proteinase activity. Mol Biol Rep 21:35-41, 1995
93. Garciá-Martinez C, Llovera M, Agell N, et al: Ubiquitin gene expression in skeletal muscle is increased during sepsis: Involvement of TNFα but not IL-1. Biochem Biophys Res Commun 217:839-844, 1995
94. 2+-activated, and ubiquitin-proteasome protelytic pathways. J Clin Invest 97:1610-1617, 1996
95. Kettelhut IC, Wing SS, Goldberg AL: Endocrine regulation of protein breakdown in skeletal muscle. Diabet Metab Rev 4:751-772, 1988
96. Bistrian BR, Schwarte J, Istfan NW: Cytokines, muscle proteolysis, and the catabolic response to infection and inflammation. Proc Soc Exp Biol Med 200:220-223, 1992
97. Ling PR, Schwartz JH, Jeevanandam M, et al: Metabolic changes in rats during a continuous infusion of recombinant interleukin 1. Am J Physiol 270:E-305-312, 1996
98. Ling PR, Schwartz JH, Bistrian BR: Mechanisms of host wasting induced by administration of cytokines in rats. Am J Physiol 272: E333-339, 1997
99. Darling G, Fraker DL, Jensen JC, et al: Cachectic effects of recombinant human tumor necrosis factor in rats. Cancer Res 50:4008-4013, 1990
100. Zamir O, Hasselgren PO, Kunkel SL, et al: Evidence that tumor necrosis factor participates in the regulation of muscle proteolysis during sepsis. Arch Surg 127:170-174, 1992
101. Zamir O, O'Brien W, Thompson R, et al: Reduced muscle protein breakdown in septic rats following treatment with interleukin-1 receptor antagonist. Int J Biochem 26:943-950, 1994
102. Goodman MN: Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 205:182-185, 1994
103. Ebisui C, Tsujinaka T, Morimoto T, et al: Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsin B and L, proteasomes) in C2C12 myotubes. Clin Sci 89:431-439, 1995
104. Black K, Garrett IR, Mundy GR: Chinese hamster ovary cells transfected with the murine IL-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor bearing nude mice. Endocrinology 128:2657-2659, 1991
105. Tsujinaka T, Ebisui C, Fujita J, et al: Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mice. Biochem Biophys Res Commun 207:168-174, 1995
106. Tsujinaka T, Fujita J, Ebisui C, et al: Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 97:244-249, 1996
107. Chai Z, Gatti S, Toniatti C, et al: Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1β: A study on IL-6-deficient mice. J Exp Med 183:311-316, 1996
108. Fattori E, Capelletti M, Costa P, et al: Defective inflammatory response in interleukin-6-deficient mice. J Exp Med 1994;180:1243-1250, 1994
109. Kozak W, Poli V, Soszynski D, et al: Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Am J Physiol 272:R661-630, 1997
110. Llovera M, Carbó N, Garciá-Marti ez C, et al: Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats. Biochem Biophys Res Commun 221:653-655, 1996
111. Hall-Agnerås M, Angerås U, Zamir O, et al: Interaction between corticosterone and tumor necrosis factor stimulated protein breakdown in rat skeletal muscle, similar to sepsis. Surgery 108:460-466, 1990
112. Mealy K, van Lanschot JJB, Robinson BG, et al: Are the catabolic effects of tumor necrosis factor mediated by glucocorticoids? Arch Surg 125:42-48, 1990
113. Tessitore L, Costelli P, Baccino FM: Pharmacological interference with cancer cachexia. Biochem J 299:71-78, 1994
114. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor a: A key component of the obesity-diabetes link. Diabetes 1994;43:1271-1278
115. Saghizadeh M, Ong JM, Garvey WT, et al: The expression of TNFα by human muscle. Relationship to insulin resistance. J Clin Invest 97:1111-1116, 1996
116. Breuillé D, Farge MC, Rose F, et al: Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. Am J Physiol 265:E660-666, 1993
117. Palombella VJ, Rando OJ, Goldberg AL, et al: The ubiquitin-proteasome pathway is required for processing of the NF-κB1 precursor protein and the activation of NF-KB. Cell 78:773-785, 1994
118. Lang CH, Dobrescu C, Bagby GJ: Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130:43-52, 1992
119. Douglas RG, Gluckman PD, Breier BH, et al: Effects of recombinant IGF-I on protein and glucose metabolism in rTNF-infused lambs. Am J Physiol 261:E606-612, 1991
120. Olefsky JM, Molina JM: Insulin resistance in man. IN Diabetes Mellitus, 4th ed, Rifkin H, Porte D Jr (eds), Elsevier, NY, 1990, pp 121-153
121. van der Poll T, Coyle SM, Barbosa K, et al: Epinephrine inhibits tumor necrosis factor a and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 97:713-719, 1996
122. Kadowaki M, Kamata T, Noguchi T: Acute effect of epinephrine on muscle proteolysis in perfused rat hindquarters. Am J Physiol 270:E961-967, 1996
123. 2-adrenoceptor agonist clenbuterol. Biosci Rep 9:615-621, 1989
124. 2-adrenergic agonist, reverses muscle wasting due to scald injury in the rat. Burns 19:26-34, 1994
125. 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest 95:2367-2372, 1995
126. Costelli P, Carbó N, Garciá-Marti ez C, et al: Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Lett 95:33-38, 1995
127. Cooney RN, Owens F, Jurasinki C, et al: Interleukin-1 receptor antagonist prevents sepsis-induced inhibition of protein synthesis. Am J Physiol 267:E636-64, 1994
128. Jurasinki CV, Vary TC: Insulin-like growth factor I accelerates protein synthesis in skeletal muscle during sepsis. Am J Physiol 269:E977-981, 1995
129. Lang CH, Fan J, Cooney RN, et al: IL-1 receptor antagonist attenuates sepsis-induced alterations in the IGF system and protein synthesis. Am J Physiol 270:E430-437, 1996
130. Fan J, Li YH, Bagby GJ, et al: Modulation of inflammation-induced changes in insulin-like growth factor (IGF)-I and IGF binding protein-1 by anti-TNF antibody. Shock 4:21-26, 1995
131. Fan J, Molina PE, Gelato MC, et al: Differential tissue regulation of insulin-like growth factor-I content and binding proteins after endotoxin. Endocrinology 134:1685-1692, 1994.
132. Wojnar MM, Fan J, Frost RA, et al: Alterations in the insulin-like growth factor system in trauma patients. Am J Physiol 268:R970-977, 1995
133. Ghahary A, Fu S, Shen YJ, et al: Differential effects of thermal injury on circulating insulin-like growth factor binding proteins in burn patients. Mol Cell Biochem 135:171-180, 1994
134. Fan J, Char D, Bagby GJ, et al: Regulation of insulin-like growth factor (IGF)-I and IGF-binding proteins by tumor necrosis factor. Am J Physiol 269:R1204-1212, 1995
135. Fan J, Wojnar MM, Theodorakis M, et al: Regulation of insulin-growth factor (IGF)-I mRNA and peptide, and IGF-I binding proteins by interleukin-1. Am J Physiol 270:R621-629, 1995
136. Dardevet D, Sornet C, Attaix D, et al: Insulin-like growth factor-1 and insulin resistance in skeletal muscle of adult and old rats. Endocrinology 134:1475-1484, 1994
137. Hong DH, Forsberg NE: Effects of serum and insulin-like growth factor I on protein degradation and protease gene expression in rat L8 myotubes. J Anim Sci 72:2279-2288, 1994
138. Vary TC, Voisin L, Cooney RN: Regulation of peptide-chain initiation in muscle during sepsis by interleukin-1 receptor antagonist. Am J Physiol 271:E513-520, 1996
139. Cooney RN, Owens E, Slaymaker D, et al: Prevention of skeletal muscle catabolism in sepsis does not impair visceral protein metabolism. Am J Physiol 270:E621-326, 1995
140. Lang CH, Cooney R, Vary TC: Central interleukin-1 partially mediates endotoxin-induced changes in glucose metabolism. Am J Physiol 271:E309-316, 1996
141. Jefferson LS, Rannels DE, Munger BL, et al: Insulin in the regulation of protein turnover in heart and skeletal muscle. Fed Proc 33:1098-1104, 1974
142. Fulks R, Li JB, Goldberg AL: Effects of insulin, glucose and amino acids on protein turnover in rat diaphragm. J Biol Chem 250:290-298, 1975
143. Narahara HT, Holloszy JO: The actions of insulin, trypsin and electrical stimulation on amino acid transport in muscle. J Biol Chem 249:5435-5443, 1974
144. Marchesini G, Forlani G, Zoli M, et al: Muscle protein breakdown in uncontrolled diabetes as assessed by urinary 3-methylhistidine excretion. Diabetologia 23:456-458, 1982
145. Nakhooda AF, Wei CN, Marliss EB: Muscle protein catabolism in diabetes: 3-Methylhistidine excretion in the spontaneously diabetic BB rat. Metab Clin Exp 29:1272-1277, 1980
146. Smith OLK, Wong CY, Gelfand RA: Skeletal muscle proteolysis in rats with acute streptozocin-induced diabetes. Diabetes 38:1117-1122, 1989
147. Smith OLK, Wong CY, Gelfand RA: Influence of glucocorticoids on skeletal muscle proteolysis in normal and diabetic-adrenalectomized eviscerated rats. Metabolism 39:641-646, 1990
148. Larbaud D, Debras E, Taillander D, et al: Euglycemic hyperinsulinemia and hyperaminoacidemia decrease skeletal muscle ubiquitin mRNA in goats. Am J Physiol 271:E505-512, 1996
149. Hotamisligil GS, Murray DL, Choy LN, et al: Tumor necrosis factor a inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 91:4854-4858, 1994
150. Cornelius P, Lee MD, Marlowe M: Monokine regulation of glucose transporter mRNA in L6 myotubes. Biochem Biophys Res Commun 165:429-436, 1989
151. Hotamisligil GS, Budavari A, Murray DL, et al: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: Central role of tumor necrosis factor a. J Clin Invest 94:1543-1549, 1994
152. Jepson MM, Bates PC, Broadbent P, et al: Relationship between glutamine concentration and protein synthesis in rat skeletal muscle. Am J Physiol 255:E166-172, 1988
153. Magnuson SR, Young AP: Murine glutamine synthetase: Cloning developmental, regulation and glucocorticoid inducibility. Dev Biol 130:536-542, 1988
154. Karner J, Roth E, Ollenschlager G, et al: Glutamine-containing dipeptides as infusion substrates in the septic state. Surgery 1989;106:893-900, 1989
155. Hickson RC, Wegrzyn LE, Osborne DF, et al: Glutamine interferes with glucocorticoid-induced expression of glutamine synthetase in skeletal muscle. Am J Physiol 270:E912-917, 1996
156. Clowes GHC Jr, George BC, Villee CA Jr, et al: Muscle proteolysis induced by a circulating peptide in patients with sepsis or trauma. N Engl J Med 308:545-552, 1983
157. McDevitt TM, Todorov PT, Beck SA: Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans. Cancer Res 55:1458-1463, 1995
158. Todorov P, Cariuk P, McDevitt T, et al: Characterization of a cancer cachectin factor. Nature 379:739-742, 1996
159. Goldberg AL: The mechanisms and functions of ATP-dependent proteases in bacterial and animals cells. Eur J Biochem 203:9-23, 1992